A Neurodevelopment Approach for a Transitional Model of Early Onset Schizophrenia

In the last decades, the conceptualization of schizophrenia has dramatically changed, moving from a neurodegenerative process occurring in early adult life to a neurodevelopmental disorder starting be-fore birth, showing a variety of premorbid and prodromal symptoms and, in relatively few cases, evolving in the full-blown psychotic syndrome. High rates of co-occurring different neurodevelopmental disorders such as Autism spectrum disorder and ADHD, predating the onset of SCZ, and neurobio-logical underpinning with significant similarities, support the notion of a pan-developmental disturbance consisting of impairments in neuromotor, receptive language, social and cognitive development. Con-sidering that many SCZ risk factors may be similar to symptoms of other neurodevelopmental psychi-atric disorders, transition processes from child & adolescent to adult systems of care should include both high risk people as well as subject with other neurodevelopmental psychiatric disorders with different levels of severity. This descriptive mini-review discuss the need of innovative clinical approaches, re-considering specific diagnostic categories, stimulating a careful analysis of risk factors and promoting the appropriate use of new and safer medications.

[1]  C. Limperopoulos,et al.  Prenatal origins of neuropsychiatric diseases , 2021, Acta paediatrica.

[2]  Jacob J. Crouse,et al.  Predicting the emergence of full-threshold bipolar I, bipolar II and psychotic disorders in young people presenting to early intervention mental health services , 2020, Psychological Medicine.

[3]  Ajit Kumar,et al.  Do Psychological Interventions Work for Psychosis in Adolescents? , 2020, Schizophrenia bulletin.

[4]  S. Wood,et al.  Adding a Dimension to the Dichotomy: Affective Processes Are Implicated in the Relationship Between Autistic and Schizotypal Traits , 2020, Frontiers in Psychiatry.

[5]  A. Tanskanen,et al.  Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia , 2020, Schizophrenia bulletin.

[6]  E. Levin,et al.  Beyond the looking glass: recent advances in understanding the impact of environmental exposures on neuropsychiatric disease , 2020, Neuropsychopharmacology.

[7]  G. Kirov,et al.  Genetic association of FMRP targets with psychiatric disorders , 2020, bioRxiv.

[8]  Ariana E. Anderson,et al.  Synaptic and Gene Regulatory Mechanisms in Schizophrenia, Autism, and 22q11.2 Copy Number Variant–Mediated Risk for Neuropsychiatric Disorders , 2020, Biological Psychiatry.

[9]  M. Leboyer,et al.  Early and very early‐onset schizophrenia compared with adult‐onset schizophrenia: French FACE‐SZ database , 2020, Brain and behavior.

[10]  P. Allard,et al.  An Understudied Dimension: Why Age Needs to Be Considered When Studying Epigenetic-Environment Interactions , 2020, Epigenetics insights.

[11]  S. Baron-Cohen,et al.  Autistic traits in adults who have attempted suicide , 2019, Molecular Autism.

[12]  住吉 太幹,et al.  Specificity and continuity of schizophrenia and bipolar disorder : relation to biomarkers , 2019 .

[13]  Manish Aligeti,et al.  Off-Label Use of Clozapine in Children and Adolescents—A Literature Review , 2019, American journal of therapeutics.

[14]  C. Pariante,et al.  Early-Life Adversity, Systemic Inflammation and Comorbid Physical and Psychiatric Illnesses of Adult Life. , 2019, Current topics in behavioral neurosciences.

[15]  N. Malas,et al.  Addressing mental health stigma: A pilot educational video intervention for caregivers to facilitate psychiatric consultation in inpatient pediatric care settings , 2019, Clinical child psychology and psychiatry.

[16]  G. Cagney,et al.  Epigenetic Factors in Schizophrenia: Mechanisms and Experimental Approaches , 2019, Molecular Neuropsychiatry.

[17]  P. Das,et al.  Understanding suicide: Focusing on its mechanisms through a lithium lens. , 2018, Journal of affective disorders.

[18]  E. de la Serna,et al.  Characterization of children and adolescents with psychosis risk syndrome: The Children and Adolescents Psychosis Risk Syndrome (CAPRIS) study , 2018, Early intervention in psychiatry.

[19]  F. Mancini,et al.  Prevalence and Clinical Significance of Symptoms at Ultra High Risk for Psychosis in Children and Adolescents with Obsessive–Compulsive Disorder: Is There an Association with Global, Role, and Social Functioning? , 2018, Brain sciences.

[20]  Fabien Ringeval,et al.  An emotional modulation model as signature for the identification of children developmental disorders , 2018, Scientific Reports.

[21]  S. Lawrie,et al.  Using Online Screening in the General Population to Detect Participants at Clinical High-Risk for Psychosis , 2018, Schizophrenia bulletin.

[22]  I. Baeza,et al.  Clinical high risk for psychosis in children and adolescents: a systematic review , 2018, European Child & Adolescent Psychiatry.

[23]  Jakob Grove,et al.  Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection , 2018, Nature Genetics.

[24]  Armin Raznahan,et al.  Neuroanatomical phenotypes in mental illness: identifying convergent and divergent cortical phenotypes across autism, ADHD and schizophrenia. , 2018, Journal of psychiatry & neuroscience : JPN.

[25]  B. Rund The research evidence for schizophrenia as a neurodevelopmental disorder. , 2018, Scandinavian journal of psychology.

[26]  K. Hall,et al.  Neuroleptic Malignant Syndrome: Diagnosis and Management. , 2018, The primary care companion for CNS disorders.

[27]  M. DelBello,et al.  Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. , 2017, Journal of the American Academy of Child and Adolescent Psychiatry.

[28]  D. Weinberger,et al.  Genetic insights into the neurodevelopmental origins of schizophrenia , 2017, Nature Reviews Neuroscience.

[29]  D. Weinberger Future of Days Past: Neurodevelopment and Schizophrenia. , 2017, Schizophrenia bulletin.

[30]  S. Leucht,et al.  Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis , 2017, European Neuropsychopharmacology.

[31]  L. Seidman,et al.  Evolving Notions of Schizophrenia as a Developmental Neurocognitive Disorder , 2017, Journal of the International Neuropsychological Society.

[32]  S. Jeon,et al.  Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome , 2017, International journal of molecular sciences.

[33]  M. Pontillo,et al.  An Overview of Recent Findings on Social Anxiety Disorder in Adolescents and Young Adults at Clinical High Risk for Psychosis , 2017, Brain sciences.

[34]  S. Ehrlich,et al.  Need for a more developmental perspective: QTc prolongation under psychotropic medication , 2017, European Child & Adolescent Psychiatry.

[35]  R. Rosenheck,et al.  Demographic and clinical correlates of substance use disorders in first episode psychosis , 2017, Schizophrenia Research.

[36]  A. Carvalho,et al.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review , 2017, Therapeutics and clinical risk management.

[37]  J. van os,et al.  A critique of the “ultra‐high risk” and “transition” paradigm , 2017, World psychiatry : official journal of the World Psychiatric Association.

[38]  A. Green,et al.  The link between schizophrenia and substance use disorder: A unifying hypothesis , 2017, Schizophrenia Research.

[39]  F. Berna,et al.  Abstract and experiential thinking differentially account for anomalous perception of reality in people with or without schizophrenia , 2017, Schizophrenia Research.

[40]  M. Kundakovic,et al.  The Epigenetic Link between Prenatal Adverse Environments and Neurodevelopmental Disorders , 2017, Genes.

[41]  R. McIntyre,et al.  Diagnostic clusters associated with an early onset schizophrenia diagnosis among children and adolescents , 2017, Human psychopharmacology.

[42]  A. Barr,et al.  Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review , 2016, Current neuropharmacology.

[43]  Wei Cheng,et al.  Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects , 2016, Nature Genetics.

[44]  G. Bersani,et al.  Cannabis use related to early psychotic onset: Role of premorbid function , 2016, Neuroscience Letters.

[45]  Giulio Genovese,et al.  Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia , 2016, Nature Neuroscience.

[46]  G. Faa,et al.  Fetal programming of neuropsychiatric disorders. , 2016, Birth defects research. Part C, Embryo today : reviews.

[47]  D. Collier,et al.  Analysis of Intellectual Disability Copy Number Variants for Association With Schizophrenia. , 2016, JAMA psychiatry.

[48]  M. De Hert,et al.  Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis , 2016, CNS Drugs.

[49]  C. Correll,et al.  Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review. , 2016, Journal of child and adolescent psychopharmacology.

[50]  M. Knapp,et al.  Early intervention for first‐episode psychosis: broadening the scope of economic estimates , 2016, Early intervention in psychiatry.

[51]  Dennis R. Grayson,et al.  Altering the course of schizophrenia: progress and perspectives , 2016, Nature Reviews Drug Discovery.

[52]  T. Kishimoto,et al.  Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis , 2016, European Child & Adolescent Psychiatry.

[53]  C. Spencer,et al.  A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium , 2016, bioRxiv.

[54]  S. Stahl,et al.  A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature , 2015, European Neuropsychopharmacology.

[55]  M. Olfson,et al.  Antipsychotic treatment of adults in the United States. , 2015, The Journal of clinical psychiatry.

[56]  Christopher S. Poultney,et al.  Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci , 2015, Neuron.

[57]  G. Kirov,et al.  Common alleles contribute to schizophrenia in CNV carriers , 2015, Molecular Psychiatry.

[58]  S. Wood,et al.  The association between autism and schizophrenia spectrum disorders: A review of eight alternate models of co-occurrence , 2015, Neuroscience & Biobehavioral Reviews.

[59]  R. Ophoff,et al.  Genome-wide burden of deleterious coding variants increased in schizophrenia , 2015, Nature Communications.

[60]  M. Pontillo,et al.  OPINION Psychosocial interventions for very early and early- onset schizophrenia: a review of treatment efficacy , 2015 .

[61]  G. Kirov,et al.  Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia , 2015, Neuron.

[62]  M. DelBello,et al.  Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. , 2015, Journal of the American Academy of Child and Adolescent Psychiatry.

[63]  M. Nordentoft,et al.  EPA guidance on the early detection of clinical high risk states of psychoses , 2015, European Psychiatry.

[64]  R. Kahn,et al.  Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST , 2014, European Neuropsychopharmacology.

[65]  Seungtai Yoon,et al.  De novo Mutations in Schizophrenia Implicate Chromatin Remodeling and Support a Genetic Overlap with Autism and Intellectual Disability , 2014, Molecular Psychiatry.

[66]  G. Kirov,et al.  The Penetrance of Copy Number Variations for Schizophrenia and Developmental Delay , 2014, Biological Psychiatry.

[67]  J. Bartlett Childhood-onset schizophrenia: what do we really know? , 2014, Health psychology and behavioral medicine.

[68]  J. Rapoport,et al.  Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. , 2013, Child and adolescent psychiatric clinics of North America.

[69]  Stephen J. Guter,et al.  Co‐occurrence of autism, childhood psychosis, and intellectual disability associated with a de novo 3q29 microdeletion , 2013, American journal of medical genetics. Part A.

[70]  K. Gadow Association of schizophrenia spectrum and autism spectrum disorder (ASD) symptoms in children with ASD and clinic controls. , 2013, Research in developmental disabilities.

[71]  D. Vancampfort,et al.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. , 2013, Schizophrenia bulletin.

[72]  K. Gadow Schizophrenia spectrum and attention-deficit/hyperactivity disorder symptoms in autism spectrum disorder and controls. , 2012, Journal of the American Academy of Child and Adolescent Psychiatry.

[73]  A. Petronis,et al.  Epigenetics of major psychosis: progress, problems and perspectives. , 2012, Trends in genetics : TIG.

[74]  Michael F. Green,et al.  Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients. , 2012, Schizophrenia bulletin.

[75]  Michael F. Green,et al.  Social cognition in schizophrenia, Part 1: performance across phase of illness. , 2012, Schizophrenia bulletin.

[76]  Peter B. Jones,et al.  Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. , 2012, The British journal of psychiatry : the journal of mental science.

[77]  John M. Davis,et al.  Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses , 2012, British Journal of Psychiatry.

[78]  S Purcell,et al.  De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia , 2011, Molecular Psychiatry.

[79]  S. Patten,et al.  Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. , 2011, Paediatrics & child health.

[80]  A. Zuddas,et al.  Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies , 2011, European Neuropsychopharmacology.

[81]  Jong H. Yoon,et al.  General and Specific Functional Connectivity Disturbances in First-Episode Schizophrenia During Cognitive Control Performance , 2011, Biological Psychiatry.

[82]  M. Rutter Research review: Child psychiatric diagnosis and classification: concepts, findings, challenges and potential. , 2011, Journal of child psychology and psychiatry, and allied disciplines.

[83]  J. Rapoport,et al.  Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder , 2011, International Journal of Developmental Neuroscience.

[84]  H. Engeland,et al.  Overlap of autistic and schizotypal traits in adolescents with Autism Spectrum Disorders , 2011, Schizophrenia Research.

[85]  G. Masi,et al.  Management of Schizophrenia in Children and Adolescents , 2011, Drugs.

[86]  M. Copenhaver,et al.  A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. , 2009, Journal of child and adolescent psychopharmacology.

[87]  Bart P F Rutten,et al.  Epigenetic mediation of environmental influences in major psychotic disorders. , 2009, Schizophrenia bulletin.

[88]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[89]  J. Boden,et al.  Outcomes for 236 patients from a 2‐year early intervention in psychosis service , 2009, Acta psychiatrica Scandinavica.

[90]  Jolene R. Bostwick,et al.  Antipsychotic‐Induced Hyperprolactinemia , 2009, Pharmacotherapy.

[91]  R. Rosenheck,et al.  A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. , 2008, The Journal of clinical psychiatry.

[92]  R. Findling,et al.  A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. , 2008, The American journal of psychiatry.

[93]  E. Walker,et al.  Childhood and current autistic features in adolescents with schizotypal personality disorder , 2008, Schizophrenia Research.

[94]  Donard S Dwyer,et al.  Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection , 2008, Pharmacological Reviews.

[95]  A. Singleton,et al.  Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.

[96]  P. Kulhara,et al.  Early intervention in schizophrenia , 2008, Indian journal of psychiatry.

[97]  Kiralee M. Hayashi,et al.  Dynamic mapping of cortical development before and after the onset of pediatric bipolar illness. , 2007, Journal of child psychology and psychiatry, and allied disciplines.

[98]  Deanna Greenstein,et al.  Cortical brain development in nonpsychotic siblings of patients with childhood-onset schizophrenia. , 2007, Archives of general psychiatry.

[99]  Robert Freedman,et al.  Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. , 2006, Schizophrenia bulletin.

[100]  J. Rapoport,et al.  Childhood onset schizophrenia: cortical brain abnormalities as young adults. , 2006, Journal of child psychology and psychiatry, and allied disciplines.

[101]  R. Kahn,et al.  The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[102]  M. Rutter,et al.  Continuities and discontinuities in psychopathology between childhood and adult life. , 2006, Journal of child psychology and psychiatry, and allied disciplines.

[103]  S. Strakowski,et al.  Open-label lithium for the treatment of adolescents with bipolar depression. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[104]  A. Yung,et al.  Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States , 2005 .

[105]  T. Kircher,et al.  EASE: Examination of Anomalous Self-Experience , 2005, Psychopathology.

[106]  J. Lieberman,et al.  Antipsychotic drug effects on brain morphology in first-episode psychosis. , 2005, Archives of general psychiatry.

[107]  Thomas F. Nugent,et al.  Dynamic mapping of human cortical development during childhood through early adulthood. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[108]  A. Addington,et al.  Pervasive developmental disorder and childhood-onset schizophrenia: comorbid disorder or a phenotypic variant of a very early onset illness? , 2004, Biological Psychiatry.

[109]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[110]  Richie Poulton,et al.  Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. , 2002, Archives of general psychiatry.

[111]  J. Rapoport,et al.  Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[112]  J. Rapoport,et al.  Update on childhood-onset schizophrenia , 2000, Current psychiatry reports.

[113]  B. Barraclough,et al.  Causes of the excess mortality of schizophrenia. , 2000, The British journal of psychiatry : the journal of mental science.

[114]  B. Dickey,et al.  Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. , 1996, American journal of public health.

[115]  D. Kivlahan,et al.  Treatment cost and rehospitalization rate in schizophrenic outpatients with a history of substance abuse. , 1991, Hospital & community psychiatry.

[116]  G Huber,et al.  The concept of basic symptoms in schizophrenic and schizoaffective psychoses. , 1989, Recenti progressi in medicina.

[117]  A. David,et al.  The nature of overinclusive thinking in schizophrenia. , 1987, Psychopathology.

[118]  D. Weinberger Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[119]  F. Mastaglia,et al.  Neuroleptic malignant syndrome , 1984, The Medical journal of Australia.

[120]  E. Bleuler [Dementia praecox or the group of schizophrenias]. , 1968, Vertex.

[121]  G. Martinotti,et al.  [Clinical use of lithium and new retard formulation: results of a survey on italian psychiatrists]. , 2020, Rivista di psichiatria.

[122]  J. Sebat,et al.  Joint Contributions of Rare Copy Number Variants and Common SNPs to Risk for Schizophrenia. , 2019, The American journal of psychiatry.

[123]  N. Kanahara,et al.  Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy , 2017, Psychotherapy and Psychosomatics.

[124]  T. van Amelsvoort,et al.  [Transitional psychiatry in the Netherlands: experiences and views of mental health professionals]. , 2017, Tijdschrift voor psychiatrie.

[125]  J. Rapoport,et al.  Common polygenic variation and risk for childhood-onset schizophrenia , 2016, Molecular Psychiatry.

[126]  C. Correll,et al.  Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. , 2015, Journal of the American Academy of Child and Adolescent Psychiatry.

[127]  M. Owen,et al.  schizophrenia-associated loci Analysis of copy number variations at 15 , 2014 .

[128]  Ian M. Anderson,et al.  Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death , 2012, Drugs.

[129]  Swapnil Gupta,et al.  What is schizophrenia: A neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis , 2010, Indian journal of psychiatry.

[130]  Deanna Greenstein,et al.  Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[131]  P. Visscher,et al.  Rare chromosomal deletions and duplications increase risk of schizophrenia , 2008, Nature.

[132]  S. Kapur Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. , 2003, The American journal of psychiatry.

[133]  A. Yung,et al.  The prodromal phase of first-episode psychosis: past and current conceptualizations. , 1996, Schizophrenia bulletin.

[134]  D. Levinson,et al.  Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. , 1990, Schizophrenia bulletin.

[135]  L. Bender Childhood schizophrenia; clinical study on one hundred schizophrenic children. , 1947, The American journal of orthopsychiatry.